EXHIBIT 99     CAUTIONARY STATEMENT UNDER PRIVATE SECURITIES
               LITIGATION REFORM ACT OF 1995 - "SAFE HARBOR" FOR
               FORWARD-LOOKING DISCLOSURES

Certain forward-looking statements are included in this Form 10-Q and may be
made by Company spokespersons based on current expectations of management. All
forward-looking statements made by the Company are subject to risks and
uncertainties. Certain factors, including but not limited to those listed below,
may cause actual results to differ materially from current expectations and
historical results.

- - Economic factors over which the Company has no control, including changes in
inflation, interest rates and foreign currency exchange rates.

- - Competitive factors including generic competition as patents on key products,
such as Prozac, expire; pricing pressures, both in the U.S. and abroad,
primarily from managed care groups and government agencies; and technological
advances and patents obtained by competitors.

- - Governmental factors including laws, regulations, and judicial decisions at
the state and federal level related to Medicare, Medicaid and healthcare reform;
and laws and regulations affecting international pricing and pharmaceutical
reimbursement.

- - The difficulties and uncertainties inherent in new product development. New
product candidates that appear promising in development may fail to reach the
market or their use may be restricted because of efficacy or safety concerns,
inability to obtain necessary regulatory approvals, difficulty or excessive
costs to manufacture, or infringement of the patents or intellectual property
rights of others.

- - Delays and uncertainties in the FDA approval process and the approval
processes in other countries, resulting in lost market opportunity.

- - Unexpected safety or efficacy concerns arising with respect to marketed
products, whether or not scientifically justified, leading to product recalls,
withdrawals or declining sales.

- - Legal factors including unanticipated litigation of product liability claims;
antitrust litigation; environmental matters; and patent disputes with
competitors (including the pending Prozac patent litigation with Barr and
Geneva, discussed in the Company's 10-K and 10-Q filings) which could preclude
commercialization of products or negatively affect the profitability of existing
products.

- - Future difficulties obtaining or the inability to obtain existing levels of
product liability insurance.

- - Changes in tax laws, including the amendment to the Section 936 income tax
credit, and future changes in tax laws related to the remittance of foreign
earnings or investments in foreign countries with favorable tax rates.

- - Changes in accounting standards promulgated by the Financial Accounting
Standards Board, the Securities and Exchange Commission, and the American
Institute of Certified Public Accountants which are adverse to the Company.

- - Internal factors such as changes in business strategies and the impact of
restructurings, impairments in asset carrying values and business combinations.